GlassScriptPhysician profile
Ryan D Christofferson
NPI 1427277037
$4,449.75
in general payments reported to CMS, 2019-2025
32 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $118 · 2021: $228 · 2022: $320 · 2023: $410 · 2024: $562 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Travel and Lodging: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.34 |
| Travel and Lodging | $432.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $1,412.86 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $453.85 | 2022-2025 | Abre, Symplicity G3, Onyx Frontier |
| Abbott Laboratories | $326.64 | 2021-2025 | Mitraclip, Cardiomems, Dragonfly Opstar |
| Boston Scientific Corporation | $297.17 | 2019-2025 | Watchman Flx, General - Atherectomy, Rotablator Rotational Atherectomy System Console Kit |
| Astrazeneca Pharmaceuticals LP | $265.97 | 2020-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $240.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $203.00 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.34 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $130.41 | 2019-2022 | |
| Esperion Therapeutics, INC. | $117.56 | 2025 | Nexletol |
| Atricure, INC. | $94.21 | 2023-2025 | Synergy Ablation System |
| Novo Nordisk INC | $91.87 | 2022-2025 | Wegovy |
| Cardiovascular Systems INC. | $75.03 | 2019-2021 | |
| Stryker Corporation | $62.92 | 2025 | Clottriever Bold Catheter |
| Pfizer INC. | $53.30 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.10 | 2019-2025 | Repatha |
| Abiomed | $41.85 | 2023-2024 | Impella |
| Kestra Medical Technology Services, INC. | $41.44 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.84 | 2019-2025 | Jardiance |
| Lantheus Medical Imaging, INC. | $33.41 | 2021-2024 | |
| Philips North America LLC | $32.48 | 2023-2024 | (6571) Eagle Eye |
| Irhythm Technologies, INC. | $27.96 | 2024 | Zio Xt Patch, Zio Monitor |
| Inari Medical, INC. | $25.09 | 2022 | |
| Amarin Pharma, INC. | $20.92 | 2020 | |
| Biotronik INC. | $18.30 | 2022 | |
| Corcept Therapeutics | $17.51 | 2019 | |
| Mannkind Corporation | $17.48 | 2019 | |
| Scpharmaceuticals INC. | $17.08 | 2025 | |
| Valeritas, INC. | $16.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2019 | |
| Bard Peripheral Vascular, INC. | $14.09 | 2021 | |
| Endo Pharmaceuticals INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Christofferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.